(3-chloro-2-methoxy-phenyl)-thiourea | 67618-13-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-chloro-2-methoxy-phenyl)-thiourea
• 英文别名: 1-(3-Chlor-2-methoxyphenyl)-thioharnstoff；(3-chloro-2-methoxyphenyl)thiourea
• CAS: 67618-13-7
• 化学式: C₈H₉ClN₂OS
• 分子量: 216.691
• InChiKey: BORWHVXHJVKJAB-UHFFFAOYSA-N

物化性质

• 沸点：
  332.0±52.0 °C(predicted)
• 密度：
  1.411±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(5-(2-bromoacetyl)-4-methylthiazol-2-yl)benzamide 、 (3-chloro-2-methoxy-phenyl)-thiourea 以 乙醇 为溶剂， 生成 N-[5-[2-(3-chloro-2-methoxyanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide
  参考文献：
  名称：

  4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing

  摘要：

  The synthesis and Delta F508-CFTR corrector activity of a 148-member methylbithiazole-based library are reported. Synthetic routes were devised and optimized to generate methylbithiazole analogs in four steps. Corrector potency and efficacy were assayed using epithelial cells expressing human Delta F508-CFTR. These structure-activity data establish that the bithiazole substructure plays a critical function; eight novel methylbithiazole correctors were identified with low micromolar potencies. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.037
• 作为产物：
  描述：

  3-氯邻茴香胺 、 苯甲酰基异硫氰酸酯 在 aq. NaOH 作用下， 以 丙酮 为溶剂， 生成 (3-chloro-2-methoxy-phenyl)-thiourea
  参考文献：
  名称：

  METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION

  摘要：

  这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法，包括向需要的受试者施用本说明书示例部分列出的化合物的有效量，或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。

  公开号：

  US20120302573A1

文献信息

• [EN] THIAZOL DERIVATIVES AS PRO -MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DÉRIVÉS DE THIAZOLE EN TANT QU'INHIBITEURS DE PRO-MÉTALLOPROTÉINASES DE MATRICE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012162468A1

  公开（公告）日：2012-11-29

  This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a thiazol derivative such as a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
• METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120302573A1

  公开（公告）日：2012-11-29

  This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

  这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法，包括向需要的受试者施用本说明书示例部分列出的化合物的有效量，或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。
• 4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing
  作者：Choong Leol Yoo、Gui Jun Yu、Baoxue Yang、Lori I. Robins、A.S. Verkman、Mark J. Kurth

  DOI：10.1016/j.bmcl.2008.03.037

  日期：2008.4

  The synthesis and Delta F508-CFTR corrector activity of a 148-member methylbithiazole-based library are reported. Synthetic routes were devised and optimized to generate methylbithiazole analogs in four steps. Corrector potency and efficacy were assayed using epithelial cells expressing human Delta F508-CFTR. These structure-activity data establish that the bithiazole substructure plays a critical function; eight novel methylbithiazole correctors were identified with low micromolar potencies. (c) 2008 Elsevier Ltd. All rights reserved.